Prior research has suggested possible gender-related disparities among patients with early stage urothelial cancer. The current analysis demonstrates that male and female patients with metastatic urothelial cancer tolerate chemotherapy similarly and achieve comparable outcomes.Background:
Although urothelial cancer is more common in men, women with urothelial cancer have inferior survival outcomes. The potential existence of gender-related disparities in patients with metastatic urothelial cancer has not been extensively explored.Patients and Methods:
Individual patient data were pooled from 8 phase II and phase III trials evaluating first-line cisplatin-based combination chemotherapy in patients with metastatic urothelial carcinoma. Adverse events, treatment delivery, response proportions, and survival outcomes were compared between male and female patients.Results:
Of the 543 patients included in the analysis, 100 patients (18%) were women. There was no significant difference in the number of cycles of chemotherapy administered or in the proportions of patients experiencing severe toxicities when comparing male and female patients. There was no difference in the survival distributions between male and female patients (P = .08); the median survival of male patients was 11.7 months (95% confidence interval [CI], 10.5–13.2) compared with 16.2 months for female patients (95% CI, 12.8–20.4). There was no significant difference in survival between men and women when controlling for baseline performance status and/or the presence of visceral metastases.Conclusion:
Female patients with metastatic urothelial cancer tolerate cisplatin-based chemotherapy similarly to male patients and achieve comparable clinical outcomes. Although gender-associated survival disparities in patients with metastatic urothelial cancer cannot be completely ruled out, if such disparities exist, they are unlikely related to tolerability or efficacy of chemotherapy.